Auer T, Uluk Y, Grasso R, Kloeckner R, Gebauer B, Kroencke T
Eur Radiol. 2025; .
PMID: 40050457
DOI: 10.1007/s00330-025-11480-w.
Auer T, Kroncke T
Eur Radiol. 2025; .
PMID: 40021502
DOI: 10.1007/s00330-025-11415-5.
Balzano E, Bernardi L, Candita G, Trizzino A, Petagna L, Bozzi E
Life (Basel). 2025; 15(2).
PMID: 40003663
PMC: 11856640.
DOI: 10.3390/life15020254.
Tomcova Z, Obertova J, Chovanec M, Sycova-Mila Z, Stefanikova K, Slachtova E
Biomedicines. 2025; 13(2).
PMID: 40002897
PMC: 11852442.
DOI: 10.3390/biomedicines13020484.
Nagpal R, Campione M, Rebuzzi S, Fratino L, Rescigno P, Bracarda S
Technol Cancer Res Treat. 2025; 24:15330338251316626.
PMID: 39989333
PMC: 11848895.
DOI: 10.1177/15330338251316626.
The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database.
Rizzo M, Pezzicoli G, Povero M, Pradelli L, Sicari E, Barbiero V
ESMO Open. 2025; 10(3):104294.
PMID: 39965361
PMC: 11876921.
DOI: 10.1016/j.esmoop.2025.104294.
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.
Pelaez I, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, Gallardo E, Alvarez-Fernandez C
Clin Transl Oncol. 2025; .
PMID: 39961959
DOI: 10.1007/s12094-025-03850-z.
Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.
Pourmir I, Benhamouda N, Tran T, Roux H, Pineau J, Gey A
J Exp Clin Cancer Res. 2025; 44(1):54.
PMID: 39953623
PMC: 11827183.
DOI: 10.1186/s13046-025-03293-y.
Characteristics and Outcomes of T1a Renal Cell Carcinoma Presenting with Metastasis.
Wang L, Guer M, Puri D, Liu F, Dhanji S, Meagher M
Cancers (Basel). 2025; 17(3).
PMID: 39941733
PMC: 11815727.
DOI: 10.3390/cancers17030364.
Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.
Pacholczak-Madej R, Drobniak A, Grela-Wojewoda A, Calik J, Viegas N, Tusien-Malecka D
Clin Exp Med. 2025; 25(1):45.
PMID: 39849293
PMC: 11759459.
DOI: 10.1007/s10238-024-01544-4.
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial.
Xu H, Yao X, He Z, Luo H, Li G, Guo J
Target Oncol. 2025; 20(1):113-125.
PMID: 39806128
DOI: 10.1007/s11523-024-01120-6.
Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.
Jozwik-Plebanek K, Saracyn M, Kolodziej M, Kaminska O, Durma A, Madra W
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770563
PMC: 11678666.
DOI: 10.3390/ph17121721.
The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma.
Quinn A, Bell S, Marrah A, Wakefield M, Fang Y
Cancers (Basel). 2024; 16(23).
PMID: 39682220
PMC: 11640273.
DOI: 10.3390/cancers16234034.
Combining Transarterial Embolization and Percutaneous Cryoablation for Early-Stage Renal Cell Carcinoma: Embolization Materials and Impacts of Tumor Size.
Terauchi M, Yamashiro T, Sawamura S, Koyama S, Nakaigawa N, Kondo K
Tomography. 2024; 10(11):1767-1779.
PMID: 39590939
PMC: 11598556.
DOI: 10.3390/tomography10110130.
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.
Frazer R, Arranz J, Estevez S, Parikh O, Krabbe L, Vasudev N
Curr Oncol Rep. 2024; 26(12):1639-1650.
PMID: 39565522
PMC: 11646210.
DOI: 10.1007/s11912-024-01613-7.
Comparison of the effects of transperitoneal and retroperitoneal robot-assisted partial nephrectomy.
Tao M, Cheng K, Xu W, Qian Z, Pan P
Pak J Med Sci. 2024; 40(10):2202-2207.
PMID: 39554681
PMC: 11568722.
DOI: 10.12669/pjms.40.10.10613.
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F
Int J Clin Oncol. 2024; 30(1):99-109.
PMID: 39549218
PMC: 11700049.
DOI: 10.1007/s10147-024-02618-9.
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland.
Pacholczak-Madej R, Drobniak A, Stoklosa L, Bidas A, Dobrzanska J, Grela-Wojewoda A
BMC Cancer. 2024; 24(1):1411.
PMID: 39548483
PMC: 11566080.
DOI: 10.1186/s12885-024-13192-8.
[Cytoreductive nephrectomy in metastatic renal cell carcinoma].
Mattigk A, Zengerling F
Urologie. 2024; 63(11):1151-1154.
PMID: 39496942
DOI: 10.1007/s00120-024-02461-w.
Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma.
Portugal I, Clavijo-Salomon M
NPJ Precis Oncol. 2024; 8(1):251.
PMID: 39496729
PMC: 11535469.
DOI: 10.1038/s41698-024-00750-3.
